Notably, GLP‐1R agonists were also associated with a significantly lower risk of OSA (OR = 0.83, 95% CI: 0.76 to 0.91, p = 6.15 × 10−5). The gene discussed is GLP1R; the disease is obstructive sleep apnea syndrome.